drugset / Trial / NCT03102398
A Study to Assess the Safety and Tolerability Profile of TR399 in Healthy Volunteers and Erectile Dysfunction Patients
Phase 1/2
Unknown
26 enrolled
Tritech Biopharmaceuticals Co., Ltd.
A2 Healthcare Taiwan Corporation · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this phase I/IIa study is to assess the safety and tolerability profile of TR399 in healthy volunteers and erectile dysfunction patients. This study will be conducted via a single-arm and open-label fashion.
Timeline
- Start
- 2017-03-31
- Primary completion
- 2018-01-31
- Completion
- 2018-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vardenafil | Small molecule | 2.5 mg | Topical |